178 related articles for article (PubMed ID: 34035415)
101. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Jabbour SK; Lee KH; Frost N; Breder V; Kowalski DM; Pollock T; Levchenko E; Reguart N; Martinez-Marti A; Houghton B; Paoli JB; Safina S; Park K; Komiya T; Sanford A; Boolell V; Liu H; Samkari A; Keller SM; Reck M
JAMA Oncol; 2021 Jun; 7(9):1-9. PubMed ID: 34086039
[TBL] [Abstract][Full Text] [Related]
102. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
103. Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
Isidori A; Cerchione C; Daver N; DiNardo C; Garcia-Manero G; Konopleva M; Jabbour E; Ravandi F; Kadia T; Burguera AF; Romano A; Loscocco F; Visani G; Martinelli G; Kantarjian H; Curti A
Front Oncol; 2021; 11():656218. PubMed ID: 34041025
[TBL] [Abstract][Full Text] [Related]
104. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.
Tsai YT; Schlom J; Donahue RN
J Exp Clin Cancer Res; 2024 Mar; 43(1):82. PubMed ID: 38493133
[TBL] [Abstract][Full Text] [Related]
105. Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.
Nakahara Y; Kouro T; Motoyama S; Miura M; Fujita K; Igarashi Y; Higashijima N; Matsuo N; Himuro H; Wei F; Horaguchi S; Tsuji K; Mano Y; Komahashi M; Saito H; Azuma K; Sasada T
Front Cell Dev Biol; 2023; 11():1324898. PubMed ID: 38469154
[No Abstract] [Full Text] [Related]
106. CD34
Perrone C; Bozzano F; Dal Bello MG; Del Zotto G; Antonini F; Munari E; Maggi E; Moretta F; Farshchi AH; Pariscenti G; Tagliamento M; Genova C; Moretta L; De Maria A
Front Immunol; 2024; 15():1332781. PubMed ID: 38390333
[TBL] [Abstract][Full Text] [Related]
107. Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation.
Verma K; Croft W; Greenwood D; Stephens C; Malladi R; Nunnick J; Zuo J; Kinsella FAM; Moss P
Front Immunol; 2023; 14():1332777. PubMed ID: 38235129
[TBL] [Abstract][Full Text] [Related]
108. Advancing cancer immunotherapy: from innovative preclinical models to clinical insights.
Craig AW; Frieboes HB; Videira PA
Sci Rep; 2024 Jan; 14(1):1205. PubMed ID: 38216668
[TBL] [Abstract][Full Text] [Related]
109. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
[TBL] [Abstract][Full Text] [Related]
110. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
Johansen AZ; Novitski SI; Hjaltelin JX; Theile S; Boisen MK; Brunak S; Madsen DH; Nielsen DL; Chen IM
Front Immunol; 2023; 14():1228907. PubMed ID: 37744345
[TBL] [Abstract][Full Text] [Related]
111. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F; Azuma K; Nakahara Y; Saito H; Matsuo N; Tagami T; Kouro T; Igarashi Y; Tokito T; Kato T; Kondo T; Murakami S; Usui R; Himuro H; Horaguchi S; Tsuji K; Murotani K; Ban T; Tamura T; Miyagi Y; Sasada T
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433717
[TBL] [Abstract][Full Text] [Related]
112. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Inoue Y; Inui N; Karayama M; Asada K; Fujii M; Matsuura S; Uto T; Hashimoto D; Matsui T; Ikeda M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Suda T
Cancer Immunol Immunother; 2023 Aug; 72(8):2717-2728. PubMed ID: 37099186
[TBL] [Abstract][Full Text] [Related]
113. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.
Zhou S; Yang H
Front Immunol; 2023; 14():1129465. PubMed ID: 37090727
[TBL] [Abstract][Full Text] [Related]
114. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
115. Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis.
Wang Y; Ni Q
Ann Med; 2023 Dec; 55(1):808-819. PubMed ID: 36892953
[TBL] [Abstract][Full Text] [Related]
116. Effect of EGFR-TKIs combined with craniocerebral radiotherapy on the prognosis of
Deng G; Tan X; Li Y; Zhang Y; Wang Q; Li J; Li Z
Front Oncol; 2023; 13():1049855. PubMed ID: 36845694
[TBL] [Abstract][Full Text] [Related]
117. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
Goh KY; Cheng TY; Tham SC; Lim DW
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831044
[TBL] [Abstract][Full Text] [Related]
118. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
Peng Y; Li Z; Fu Y; Pan Y; Zeng Y; Liu J; Xiao C; Zhang Y; Su Y; Li G; Wu F
Front Oncol; 2023; 13():1011810. PubMed ID: 36761954
[TBL] [Abstract][Full Text] [Related]
119. Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α-STAT3 Axis.
Virgilio T; Bordini J; Cascione L; Sartori G; Latino I; Molina Romero D; Leoni C; Akhmedov M; Rinaldi A; Arribas AJ; Morone D; Seyed Jafari SM; Bersudsky M; Ottolenghi A; Kwee I; Chiaravalli AM; Sessa F; Hunger RE; Bruno A; Mortara L; Voronov E; Monticelli S; Apte RN; Bertoni F; Gonzalez SF
Cancer Immunol Res; 2022 Dec; 10(12):1525-1541. PubMed ID: 36206577
[TBL] [Abstract][Full Text] [Related]
120. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
